目的 評(píng)價(jià)注射用丹參多酚酸對(duì)急性大動(dòng)脈粥樣硬化型腦梗死患者的臨床療效及安全性。方法 收集2016年9月-2017年8月山西醫(yī)科大學(xué)第一醫(yī)院收治的急性腦梗死患者100例，隨機(jī)分為對(duì)照組及觀察組，各50例。對(duì)照組予常規(guī)治療，觀察組在對(duì)照組基礎(chǔ)上加用注射用丹參多酚酸，每次0.13 g加入250 mL 0.9%氯化鈉中靜滴，1次/d，治療周期均為14 d。比較兩組患者治療前和治療后神經(jīng)功能缺損（NIHSS）評(píng)分、Barthel指數(shù)（BI）評(píng)分、血纖維蛋白原（FIB）、肝腎功能、心肌酶的變化以及不良反應(yīng)。結(jié)果 治療后，兩組的NIHSS評(píng)分和BI評(píng)分均有顯著改善（P<0.05），且觀察組NIHSS評(píng)分低于對(duì)照組（P<0.05），BI評(píng)分高于對(duì)照組（P<0.05）；觀察組血FIB與治療前比較具有統(tǒng)計(jì)學(xué)差異（P<0.05）。兩組患者用藥前后肝腎功能、心肌酶未見明顯變化，用藥過程中無不良事件發(fā)生。結(jié)論 注射用丹參多酚酸可以改善急性大動(dòng)脈粥樣硬化型腦梗死患者的NIHSS評(píng)分和BI評(píng)分，并能在一定程度上降低血FIB水平；對(duì)患者的肝功能、腎功能、心肌酶等無明顯影響，副作用小。

Objective To evaluate the clinical effect and safety of Salvianolic Acids for Injection (SAFI) in treatment of acute aortic atherosclerotic cerebral infarction. Methods A total of 100 patients of acute aortic atherosclerotic cerebral infarction in The First Hosipital of Shanxi Medical University from September 2016 to August 2017 were selected and were randomly divided into the observation group and the control group. The patients in the control group received routine medicine therapy, and the patients in the treatment group received SAFI 0.13 g added for 0.9% sodium chloride 250 mL intravenous drip qd in addition to the treatment of control group. Patients treated once per day and 14 d for one course of treatment, and the prognosis of the two groups were observed by NIHSS scores and BI scores, fibrinogen (FIB), liver and kidney function, myocardial enzymes and incidence of adverse reactions. Results After treatment, the NIHSS score and BI score in both groups were significantly improved (P<0.05), and the NIHSS score in the observation group was lower than that in the control group (P<0.05), and the BI score was higher than that in the control group (P<0.05). The FIB of blood in the experimental group was significantly different from that before treatment (P<0.05). The liver and kidney functions and myocardial enzymes of the two groups did not change significantly before and after treatment, and no adverse events occurred during the medication process. Conclusion SAFI can improve NIHSS scores and BI scores of patients with acute atherosclerotic cerebral infarction, and reduce blood FIB level to a certain extent. Additionally, it has no obvious effect on liver function, kidney function and myocardial enzyme, and has little side effect.

吳階平醫(yī)學(xué)基金會(huì)臨床項(xiàng)目（320.6750.16132）